A seasoned investment and operating executive with experience in private equity, growth equity and corporate M&A, Michael G. Hansen focuses on sourcing, diligencing and scaling companies across healthcare and technology sectors. He has led deal execution, portfolio company operational improvement and capital formation efforts; profile of a market-oriented investor bridging strategic operations and financial structuring for mid-market transactions.
A seasoned investment and operating executive with experience in private equity, growth equity and corporate M&A, Michael G. Hansen focuses on sourcing, diligencing and scaling companies across healthcare and technology sectors. He has led deal execution, portfolio company operational improvement and capital formation efforts; profile of a market-oriented investor bridging strategic operations and financial structuring for mid-market transactions.
Combines private equity rigor with operating-led value creation, prioritizing mid-market healthcare and technology businesses where operational improvements and product-led growth can unlock scale. Emphasizes deep due diligence, disciplined capital structuring, and active board-level involvement to drive margin expansion and commercial acceleration. Prefers growth-at-scale opportunities with clear pathways to margin improvement, recurring revenue models, and defensible technology or clinical differentiation; typically horizon of 3–7 years with calibrated downside protection and staged capital deployment tied to operational milestones.
Combines private equity rigor with operating-led value creation, prioritizing mid-market healthcare and technology businesses where operational improvements and product-led growth can unlock scale. Emphasizes deep due diligence, disciplined capital structuring, and active board-level involvement to drive margin expansion and commercial acceleration. Prefers growth-at-scale opportunities with clear pathways to margin improvement, recurring revenue models, and defensible technology or clinical differentiation; typically horizon of 3–7 years with calibrated downside protection and staged capital deployment tied to operational milestones.
| Trades 2138 | Longs Won 1455/2138 68% | Profit Factor 5.24 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $136,516.44 |
| Average Win $64,085.63 | Best Trade (Oct 16) $2.1M | Sharpe Ratio -10.4 |
| Average Loss -$26,054.4 | Worst Trade (Oct 16) -$1.08M | Z-Score 4.52 (100%) |
| Commissions $0 | Avg. Trade Length 1y 1w 4d | Expectancy $34,627.29 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 13,333 | 12,000 | 10,667 | 9,333 | 8,000 | 6,667 | 5,333 | 4,000 | 2,667 | 1,333 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 27,377 | $7.46M | $9.36M | - | $1.91M | 25.55% | -0.28% |
ABBV AbbVie Inc. | 3,172 | $726,981.77 | $898,944.77 | - | $171,963 | 23.65% | -0.028% |
ABT Abbott Laboratories | 18,164 | $1.84M | $1.9M | - | $66,248.21 | 3.61% | +2.286% |
ACYN FT Vest Laddered Autocallable Barrier & Income ETF | 869,068 | $18.1M | $18.02M | - | -$79,974.55 | -0.44% | 0.0 |
ACYS FT Vest Laddered Autocallable Barrier & Resilient Income ETF | 429,323 | $8.83M | $8.78M | - | -$51,032.64 | -0.58% | -0.049% |
ADI Analog Devices, Inc. | 4,734 | $1.11M | $1.91M | - | $799,765.63 | 71.89% | +0.094% |
AFLG First Trust Active Factor Large Cap ETF | 79,090 | $2.78M | $3.57M | - | $790,029.79 | 28.39% | +0.4% |
AJG Arthur J. Gallagher & Co. | 7,641 | $2.04M | $1.91M | - | -$125,211.94 | -6.15% | +5.51% |
AMD Advanced Micro Devices, Inc. | 1,248 | $724,975.24 | $701,663.02 | - | -$23,312.22 | -3.22% | -1.505% |
AMGN Amgen Inc. | 1,532 | $510,507.56 | $664,933.96 | - | $154,426.4 | 30.25% | +1.859% |
AMZN Amazon.com Inc | 21,427 | $4.54M | $5.46M | - | $917,721.43 | 20.21% | +0.268% |
AVGO Broadcom Inc. | 10,167 | $2.42M | $3.5M | - | $1.08M | 44.74% | -0.555% |
AZN AstraZeneca PLC American Depositary Shares | 10,855 | $2.14M | $1.76M | - | -$382,034.5 | -17.84% | 0.0 |
BAC Bank of America Corporation | 27,056 | $854,426.16 | $1.4M | - | $544,369.04 | 63.71% | +0.603% |
BBNX Beta Bionics Inc. | 10,000 | $170,000 | $173,100 | - | $3,100 | 1.82% | +2.608% |
BIL SPDR Bloomberg 1-3 Month T-Bill ETF | 70,392 | $6.46M | $6.44M | - | -$14,012.01 | -0.22% | +0.027% |
BILS SPDR Bloomberg 3-12 Month T-Bill ETF | 12,051 | $1.2M | $1.2M | - | -$3,144.58 | -0.26% | +0.015% |
BMY Bristol-Myers Squibb Company | 24,964 | $1.56M | $1.51M | - | -$45,683.52 | -2.93% | +2.176% |
BOND PIMCO Active Bond Exchange-Traded Fund | 31,376 | $2.73M | $2.76M | - | $28,550.4 | 1.05% | +0.71% |
BRK-B Berkshire Hathaway Inc. | 4,201 | $2.06M | $2.21M | - | $146,918.97 | 7.12% | -0.055% |